BioAlliance to market Loramyc in France at 4 euros per day

France-based BioAlliance Pharma SA says that the Economic Committee for French Health Products has accepted the price of 4 euros ($5.3) per day for Loramyc (miconazole Lauriad) 50mg for the treatment of oropharyngeal candidiasis for immunocompromised patients, in particular those with head or neck cancer after radiotherapy and for patients with HIV. This pricing agreement on follows the favorable opinion of France's health authority on the reimbursement of Loramyc at 65%. The agent will be added to the lists of drugs that are reimbursed for patients covered by social security and of medicines approved for use by hospitals and various public services.